In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Muhammed Murtaza and Dr. Thomas Slavin about liquid biopsies

Murtaza is Assistant Professor and co-Director of the Center for Noninvasive Diagnostics at TGen in Phoenix, AZ, and Dr. Slavin is Assistant Clinical Professor, Departments of Medical Oncology & Therapeutics Research and Population Sciences, Division of Clinical Cancer Genomics at City of Hope Comprehensive Cancer Center in Duarte, California.

Hofland talks with Murtaza and Slavin specifically about a test called TARDIS — which stands for TARgeted DIgital Sequencing. This test, according to a study published earlier this year, is as much as 100 times more sensitive than other blood-based cancer monitoring tests. TARDIS is a “liquid biopsy” that specifically identifies and quantifies small fragments of cancer DNA circulating in the patient’s bloodstream, known as circulating tumor DNA (ctDNA).
About Onco’Zine
The Onco’Zine Brief is developed in collaboration with the online journal, Onco’Zine at – where you can find additional information and the latest news about cancer, cancer diagnosis and treatment, and cancer prevention.

How to support The Onco’Zine Brief
For more information about supporting The Onco’Zine Brief, check our online journal Onco’Zine at www.Onco’ or visit Patreaon at

If you’re living in the United States and want to receive our Newsletter, text the word CANCER to 66866 – and we’ll make sure that you’ll receive our newsletter which includes an overview of the latest news in oncology and hematology.

For more information about TARgeted DIgital Sequencing (TARDIS):
– Garcia D. Federal Grant helps TGen Refine Cancer-detection Blood Tests for Breast Cancer Patients. Onco’Zine – October 15, 2019 –
– Hofland P. New ‘Liquid Biopsy’ Helps to Improve Breast Cancer Diagnostics and Avoid Unnecessary Surgeries – August 8, 2019 –